Garfield Alastair
Chief Scientific Officer
Garfield Alastair has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 17, 2026.
On the most recent filing, Garfield Alastair is listed as Chief Scientific Officer at RHYTHM PHARMACEUTICALS, INC. Inside the rolling window, Garfield Alastair reported no open-market purchases and 1 open-market sale totaling $913K in RYTM.
Companies traded
Other insiders at RYTM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$913K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Garfield Alastair made?
Garfield Alastair has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.
Which companies does Garfield Alastair trade?
Garfield Alastair has filed SEC Form 4 disclosures for 1 company, including RYTM.
When was Garfield Alastair's most recent SEC Form 4 filing?
Garfield Alastair's most recent SEC Form 4 filing on Tracefour is dated Aug 17, 2026.
What is Garfield Alastair's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Garfield Alastair is listed as Chief Scientific Officer.
What is Garfield Alastair's total buy and sell value in the current window?
Inside the rolling retention window, Garfield Alastair bought $0 and sold $913K based on SEC Form 4 filings.
What was Garfield Alastair's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,763 RYTM shares on 2026-08-13, worth $913K, per SEC Form 4 filings.